KMDA

TentativeAI MemoPost-earnings T+3

Kamada

As of 2026-08-17/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 earnings beat with FY2026 guidance reaffirmed • 2026-08-12

Base target: $9 / p=55% prob

Biggest risk

Management reaffirmed rather than raised guidance despite strong first-half results. Gross margin declined to 41% in Q2 from 42% a year earlier and to 42% for H1 from 45%, while Q4 plasma revenue, biosimilar expansion, MENA growth, CYTOGAM utilization and pending M&A remain execution-dependent. CFO succession adds uncertainty, and post-print analyst revisions are unavailable.

Invalidation

Break below $6 or thesis failure.

What would change my mind?

The Q2 print supports a positive operating trajectory: record revenue, adjusted EBITDA and cash generation, with revenue and EBITDA approximately at 50% of the respective FY2026 guidance midpoints. The plasma agreement, dividend, MENA and biosimilar expansion, and CYTOGAM research provide multiple sources of potential longer-term support.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-17

Base target

p=55%

Bull target

$12

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

MENA distribution partnerships and Israeli biosimilar launches
CYTOGAM post-marketing research program
The Q2 print supports a positive operating trajectory: record revenue, adjusted EBITDA and cash generation, with revenue and EBITDA approximately at 50% of the respective FY2026 guidance midpoints.

BearKey bullets

Back-end-loaded FY2026 guidance depends on continued demand and successful second-half execution.
Biosimilar launches, MENA distribution expansion and M&A or business-development activity may not convert into revenue on schedule.
CFO departure effective December 31, 2026 creates transition and continuity risk.

WatchKey bullets

Q2 earnings beat with FY2026 guidance reaffirmed

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $9 (p=55%)

Target spread vs base: +35% / -26%

Scenario probabilities

Bull Target: $12 (p=20%)Base Target: $9 (p=55%)Bear Target: $6 (p=25%)

Commentary

The company source and stored earnings transcript confirm a strong Q2 and reaffirmed outlook; an AP/Zacks snapshot also reported revenue and EPS above surveyed expectations. The August 14 anchor price of $7.58 and August 17 finance quote near $7.65 suggest a modestly positive but not decisive post-print reaction. Analyst revisions, options data, short interest and social coverage are unavailable, so this remains a low-coverage monitoring thesis rather than a high-conviction re-rating case.

As of 2026-08-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

MENA distribution partnerships and Israeli biosimilar launches
CYTOGAM post-marketing research program

Scenarios

Bull Target (Scenario probability)

$12 / p=20% prob

Base Target (Scenario probability)

$9 / p=55% prob

Bear Target (Scenario probability)

$6 / p=25% prob

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.62

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-12
Q2 earnings beat with FY2026 guidance reaffirmed
Q2 revenue reached a record $54.9 million, net income was $9.3 million, and management reaffirmed FY2026 revenue guidance of $200-$205 million and adjusted EBITDA guidance of $50-$53 million. The company cited stronger KEDRAB, VARIZIG, HEPAGAM and operating cash flow. [#IR-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q2]
Prob 90.00% • Move 5.00% • Priced-in 75.00%
EVENT2026-09-17
Cash dividend payment
The company declared a $0.17 per-share dividend payable September 17, 2026, citing record first-half results and liquidity. [#IR-2026-08-17]
Prob 95.00% • Move 2.00% • Priced-in 85.00%
EVENT2026-10-01
Initial plasma sales under three-year agreement
Kamada expects initial commercial sales under its approximately $50 million plasma supply agreement to begin in Q4 2026, with the contribution included in current guidance. Timing and ramp remain execution-dependent. [#IR-2026-08-12]
Prob 65.00% • Move 12.00% • Priced-in 50.00%
EVENT2026-12-31
CFO transition at year-end
CFO Chaime Orlev plans to leave effective December 31, 2026, while Kamada searches for a successor. Transitional support is planned, but management continuity remains a monitoring item. [#IR-2026-08-12]
Prob 70.00% • Move -5.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

MENA distribution partnerships and Israeli biosimilar launches
2026-12-31
Management expects additional biosimilar launches in Israel and continued expansion into the MENA region through new distribution agreements and product registrations. The opportunity is strategically relevant but remains execution-dependent. [#IR-2026-08-12]
Prob 45% • Move 8% • Priced-in 35%
CYTOGAM post-marketing research program
2026-12-31
Kamada highlighted study findings associated with improved outcomes in high-risk lung-transplant recipients and is continuing post-marketing research intended to support CYTOGAM utilization. Commercial impact remains unconfirmed. [#IR-2026-07-13]
Prob 40% • Move 8% • Priced-in 25%

Risks

Back-end-loaded FY2026 guidance depends on continued demand and successful second-half execution.
Biosimilar launches, MENA distribution expansion and M&A or business-development activity may not convert into revenue on schedule.
CFO departure effective December 31, 2026 creates transition and continuity risk.
CYTOGAM post-marketing findings are encouraging but do not guarantee utilization or financial impact; regulatory and international-market risks remain.
Gross-margin compression could offset revenue growth if product and market mix remain unfavorable.
Q4 timing and ramp of the plasma supply agreement remain uncertain, with concentration around a single strategic contract.

Peers

Symbol	Summary
ADMA	Direct operating comparator: ADMA Biologics is a commercial, vertically integrated specialty plasma-derived biologics company with FDA-approved immune-globulin products and plasma-collection operations. Its U.S.-focused product mix and scale differ from Kamada, so it is a qualitative rather than valuation-grade comparable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-17

Loading AI feed…

Symbol

Summary

ADMA

Direct operating comparator: ADMA Biologics is a commercial, vertically integrated specialty plasma-derived biologics company with FDA-approved immune-globulin products and plasma-collection operations. Its U.S.-focused product mix and scale differ from Kamada, so it is a qualitative rather than valuation-grade comparable.